Proposal for a synthetic lethality therapy using the paralog dependence of cancer cells - Response

Cancer Research

Volumn 74, Issue 17, 2014, Pages 4948-4950

  Oike, Takahiro ^a,b   Ogiwara, Hideaki ^a   Nakano, Takashi ^b   Kohno, Takashi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA HELICASE; NUCLEAR PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

ANIMAL; APOPTOSIS; FEMALE; GENETICS; HUMAN; MALE; NON SMALL CELL LUNG CANCER;

ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; DNA HELICASES; FEMALE; HUMANS; MALE; NUCLEAR PROTEINS; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS;

EID: 84907056059     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0674     Document Type: Letter

References (7)

1. Oike T, Ogiwara H, Tominaga Y, Ito K, Ando O, Tsuta K, et al. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res 2013;73:5508-18.
2. Hoffman GR, Rahal R, Buxton F, Xiang K, McAllister G, Frias E, et al. Functional epigenetics approach identifies BRM/ SMARCA2 as a critical synthetic lethal target in BRG1- deficient cancers. Proc Natl Acad Sci U S A 2014;111: 3128-33.
3. Wilson BG, Helming KC, Wang X, Kim Y, Vazquez F, Jagani Z, et al. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol Cell Biol 2014;34: 1136-44.
4. Helming KC, Wang X, Wilson BG, Vazquez F, Haswell JR, Manchester HE, et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med 2014;20:251-4.
5. Reisman DN, Sciarrotta J, Wang W, Funkhouser WK, Weissman BE. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res 2003;63:560-6.
6. Reisman DN, Strobeck MW, Betz BL, Sciariotta J, Funkhouser W Jr, Murchardt C, et al. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs. CD44 expression. Oncogene 2002;21:1196-207.
7. Kahali B, Gramling SJ, Marquez SB, Thompson K, Lu L, Reisman D. Identifying targets for the restoration and reactivation of BRM. Oncogene 2014;33:653-64.